|
AU2003275958A1
(en)
*
|
2003-08-25 |
2005-03-10 |
Pieris Proteolab Ag |
Muteins of tear lipocalin
|
|
EP2899277A1
(en)
|
2004-11-26 |
2015-07-29 |
Pieris AG |
Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
|
|
US7611847B2
(en)
|
2005-06-01 |
2009-11-03 |
Agency For Science, Technology And Research |
Method for identifying an intestinal phenotype
|
|
US8216855B2
(en)
|
2006-02-13 |
2012-07-10 |
Agency For Science, Technology And Research |
Method of processing a biological and/or chemical sample
|
|
EP2004328B1
(en)
|
2006-03-09 |
2014-06-04 |
Agency for Science, Technology and Research |
Method for performing a reaction in a droplet
|
|
EP1996613B1
(en)
*
|
2006-03-20 |
2014-04-30 |
Technische Universität München |
Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
|
|
DK2046820T3
(da)
|
2006-08-01 |
2011-02-07 |
Pieris Ag |
Muteiner af tåre-lipocalin og fremgangsmåder til opnåelse deraf
|
|
ES2354653T3
(es)
*
|
2006-08-01 |
2011-03-16 |
Pieris Ag |
Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas.
|
|
US9874501B2
(en)
|
2006-11-24 |
2018-01-23 |
Curiox Biosystems Pte Ltd. |
Use of chemically patterned substrate for liquid handling, chemical and biological reactions
|
|
WO2010120249A1
(en)
|
2009-04-17 |
2010-10-21 |
Curiox Biosystems Pte Ltd |
Use of chemically patterned substrate for liquid handling, chemical and biological reactions
|
|
WO2008063135A1
(en)
|
2006-11-24 |
2008-05-29 |
Agency For Science, Technology And Research |
Apparatus for processing a sample in a liquid droplet and method of using the same
|
|
WO2008127199A1
(en)
|
2007-04-13 |
2008-10-23 |
Agency For Science, Technology And Research |
Methods of controlling tumorigenesis and diagnosing the risk thereof
|
|
EP2217240A4
(en)
|
2007-11-02 |
2012-09-12 |
Agency Science Tech & Res |
METHOD AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOR
|
|
US10725020B2
(en)
|
2007-11-14 |
2020-07-28 |
Curiox Biosystems Pte Ltd. |
High throughput miniaturized assay system and methods
|
|
WO2013114217A1
(en)
|
2012-02-05 |
2013-08-08 |
Curiox Biosystems Pte Ltd. |
Array plates and methods for making and using same
|
|
CN104650235A
(zh)
|
2007-11-30 |
2015-05-27 |
葛兰素集团有限公司 |
抗原结合构建体
|
|
EP2245054B1
(en)
*
|
2008-01-30 |
2018-11-28 |
Pieris Pharmaceuticals GmbH |
Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same
|
|
US20090274623A1
(en)
*
|
2008-01-30 |
2009-11-05 |
General Electric Company |
In vivo imaging agents for met receptor tyrosine kinase
|
|
WO2009132351A2
(en)
*
|
2008-04-25 |
2009-10-29 |
University Of Medicine And Dentistry Of New Jersey |
Anti-sense microrna expression vectors
|
|
US9102920B2
(en)
|
2008-05-06 |
2015-08-11 |
Agency For Science, Technology And Research |
Method of effecting de-differentiation of a cell
|
|
CL2009001076A1
(es)
|
2008-05-06 |
2010-09-24 |
Glaxo Group Ltd |
Nanoparticulas que comprende una sustancia formadora de particulas y una proteina; composicion que comprende dichas nanoparticulas; procedimiento para suministrar una proteina a traves de la membrana hematoencefalica; uso de la composicion para profilaxis o tratar enfermedades del sistema nervioso central.
|
|
JP5711118B2
(ja)
|
2008-06-24 |
2015-04-30 |
テクニッシュ ウニヴェルジテート ミュンヘン |
所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン
|
|
JP2010074915A
(ja)
*
|
2008-09-17 |
2010-04-02 |
Jtekt Corp |
モータ制御装置及び電動パワーステアリング装置
|
|
WO2010044752A1
(en)
|
2008-10-13 |
2010-04-22 |
Agency For Science, Technology And Research |
Amphiphilic polymers and nanocrystals coated therewith
|
|
DK2189539T4
(da)
|
2008-11-21 |
2018-09-17 |
Chimera Biotec Gmbh |
Konjugatkomplekser til analytdetektering
|
|
UY32341A
(es)
|
2008-12-19 |
2010-07-30 |
Glaxo Group Ltd |
Proteínas de unión antígeno novedosas
|
|
WO2010097385A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Antigen-binding constructs
|
|
JP2012518400A
(ja)
|
2009-02-24 |
2012-08-16 |
グラクソ グループ リミテッド |
多価および／または複数特異的ｒａｎｋｌ結合性構築物
|
|
WO2010097386A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Antigen-binding constructs
|
|
SG177395A1
(en)
|
2009-07-07 |
2012-02-28 |
Agency Science Tech & Res |
Methods of identifying a pair of binding partners
|
|
CA2768330A1
(en)
|
2009-07-28 |
2011-02-03 |
F. Hoffmann-La Roche Ag |
Non-invasive in vivo optical imaging method
|
|
EP2461800A2
(en)
|
2009-08-05 |
2012-06-13 |
Pieris AG |
Controlled release formulations of lipocalin muteins
|
|
DK2510357T3
(da)
*
|
2009-12-07 |
2016-07-18 |
Pieris Ag |
Muteiner af human lipocalin 2 (lcn2, hngal) med affinitet til et specifikt mål
|
|
WO2011078794A1
(en)
|
2009-12-22 |
2011-06-30 |
Agency For Science, Technology And Research |
Sers-based analyte detection
|
|
AU2011209713B2
(en)
|
2010-01-28 |
2014-04-03 |
Glaxo Group Limited |
CD127 binding proteins
|
|
KR101341640B1
(ko)
*
|
2010-02-05 |
2013-12-16 |
한국전자통신연구원 |
단백질 미세 구조 분석 방법 및 단백질 미세 구조 분석용 어레이
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
AU2011230537C1
(en)
|
2010-03-26 |
2018-08-02 |
Trustees Of Dartmouth College |
Vista regulatory T cell mediator protein, vista binding agents and use thereof
|
|
JP6145404B2
(ja)
|
2010-05-07 |
2017-06-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
エクスビボでの細胞の検出のための診断的方法
|
|
UY33421A
(es)
|
2010-06-03 |
2011-12-30 |
Glaxo Wellcome House |
Proteinas de union al antígeno humanizados
|
|
DK2580236T3
(da)
|
2010-06-08 |
2019-06-11 |
Pieris Pharmaceuticals Gmbh |
Muteiner af tåre-lipocalin, der binder til il-4-r-alfa
|
|
US9878328B2
(en)
|
2010-07-23 |
2018-01-30 |
Curiox Biosystems Pte Ltd. |
Apparatus and method for multiple reactions in small volumes
|
|
RU2625011C2
(ru)
|
2010-08-16 |
2017-07-11 |
Пиерис АГ |
Белки, связывающиеся с гепсидином
|
|
US8987415B2
(en)
|
2010-09-07 |
2015-03-24 |
Technische Universitaet Muenchen |
Recombinant bacterial lipocalin blc and uses thereof
|
|
JP6121904B2
(ja)
*
|
2010-09-08 |
2017-04-26 |
ハロザイム インコーポレイテッド |
条件的活性治療用タンパク質を評価および同定する、または発展させる方法
|
|
EP2640740B1
(en)
*
|
2010-11-15 |
2017-03-15 |
Pieris Pharmaceuticals GmbH |
Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
|
|
UY33743A
(es)
|
2010-11-23 |
2012-06-29 |
Glaxo Group Ltd |
Proteínas de unión a antígenos
|
|
JP2014501725A
(ja)
|
2010-11-24 |
2014-01-23 |
グラクソ グループ リミテッド |
Ｈｇｆを標的とする多特異的抗原結合タンパク質
|
|
DK2646552T3
(da)
|
2010-12-02 |
2017-10-23 |
Pieris Pharmaceuticals Gmbh |
Muteiner af human lipocalin 2 med affinitet til ctla-4
|
|
WO2012136685A1
(en)
|
2011-04-04 |
2012-10-11 |
Pieris Ag |
Methods and compositions for anti-vegf and anti-c-met therapy
|
|
CA2830923A1
(en)
|
2011-04-15 |
2012-10-18 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
|
PT3415531T
(pt)
|
2011-05-27 |
2023-09-12 |
Glaxo Group Ltd |
Proteínas de ligação a bcma (cd269/tnfrsf17
|
|
AU2012269720B2
(en)
|
2011-06-13 |
2015-01-22 |
Csl Limited |
Antibodies against G-CSFR and uses thereof
|
|
US9225772B2
(en)
|
2011-09-26 |
2015-12-29 |
Knoa Software, Inc. |
Method, system and program product for allocation and/or prioritization of electronic resources
|
|
EP2771351B1
(en)
|
2011-10-28 |
2017-06-14 |
Patrys Limited |
Pat-lm1 epitopes and methods for using same
|
|
AU2012350654C1
(en)
|
2011-12-12 |
2018-05-10 |
Pieris Ag |
Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
|
|
DK3453400T3
(da)
|
2011-12-13 |
2021-04-06 |
Pieris Pharmaceuticals Gmbh |
Fremgangsmåder til forebyggelse eller behandling af visse forstyrrelser ved inhibering af binding af il-4 og/eller il-13 til deres respektive receptorer
|
|
EP2797622B1
(en)
|
2011-12-30 |
2016-10-12 |
Halozyme, Inc. |
Ph20 polypeptide variants, formulations and uses thereof
|
|
AP2014007792A0
(en)
|
2012-01-09 |
2014-07-31 |
Pieris Ag |
Methods for preventing, treating or diagnosing disorders
|
|
EP2809679A1
(en)
|
2012-01-31 |
2014-12-10 |
Technische Universität München |
Muteins of a1m lipocalin and method of production therefor
|
|
SI2814843T1
(sl)
|
2012-02-13 |
2020-11-30 |
Agency For Science, Technology And Research |
IL-beta nevtralizirajoča humana monoklonska protitelesa
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
WO2013174783A1
(en)
|
2012-05-23 |
2013-11-28 |
Pieris Ag |
Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
|
|
WO2013189521A1
(en)
|
2012-06-19 |
2013-12-27 |
Waclawczyk Simon |
Method of generating cells of hepatocyte phenotype
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
CN105246507B
(zh)
|
2012-09-07 |
2019-01-25 |
达特茅斯大学理事会 |
用于诊断和治疗癌症的vista调节剂
|
|
SG11201502538TA
(en)
|
2012-11-08 |
2015-05-28 |
Hoffmann La Roche |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
|
WO2014076321A1
(en)
|
2012-11-19 |
2014-05-22 |
Pieris Ag |
Novel specific-binding polypeptides and uses thereof
|
|
SG11201505856TA
(en)
*
|
2013-03-14 |
2015-08-28 |
Daiichi Sankyo Co Ltd |
Novel binding proteins for pcsk9
|
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ｐｈ２０玻尿酸酶變異體及其用途
|
|
US9557318B2
(en)
|
2013-07-09 |
2017-01-31 |
Curiox Biosystems Pte Ltd. |
Array plates for washing samples
|
|
AU2014329437B2
(en)
|
2013-10-06 |
2018-10-18 |
F. Hoffmann-La Roche Ag |
Modified Pseudomonas exotoxin A
|
|
CN105873608A
(zh)
|
2013-11-28 |
2016-08-17 |
杰特有限公司 |
治疗肾病的方法
|
|
AU2014366837B2
(en)
|
2013-12-18 |
2020-06-25 |
B-Creative Sweden Ab |
Method of treating wounds
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
DK3087098T3
(da)
|
2013-12-24 |
2020-06-08 |
Janssen Pharmaceutica Nv |
Anti-Vista-antistoffer og -fragmenter
|
|
AU2015205530B8
(en)
|
2014-01-13 |
2019-09-19 |
Pieris Pharmaceuticals Gmbh |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
|
LU92409B1
(en)
|
2014-03-21 |
2015-09-22 |
Philipps Universit T Marburg |
Means and methods for itaconic acid production
|
|
ES2823563T3
(es)
*
|
2014-05-22 |
2021-05-07 |
Pieris Pharmaceuticals Gmbh |
Polipéptidos de unión específica novedosos y usos de los mismos
|
|
JP6997619B2
(ja)
|
2014-06-11 |
2022-01-17 |
キャシー・エイ・グリーン |
液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
CN113372434B
(zh)
|
2014-11-14 |
2024-06-04 |
豪夫迈·罗氏有限公司 |
包含tnf家族配体三聚体的抗原结合分子
|
|
JP2018505911A
(ja)
|
2014-12-05 |
2018-03-01 |
イミュネクスト，インコーポレーテッド |
推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
|
|
WO2016113203A1
(en)
|
2015-01-12 |
2016-07-21 |
Pieris Ag |
Engineered t cells and uses therefor
|
|
JP6839087B2
(ja)
|
2015-01-28 |
2021-03-03 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
血管新生に特異的な新規のタンパク質
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
JP6783797B2
(ja)
|
2015-05-04 |
2020-11-11 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
抗がん融合ポリペプチド
|
|
AU2016258952C1
(en)
*
|
2015-05-04 |
2020-12-24 |
Pieris Pharmaceuticals Gmbh |
Proteins specific for CD137
|
|
EP3298029A1
(en)
|
2015-05-18 |
2018-03-28 |
Pieris Pharmaceuticals GmbH |
Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
|
|
LT3298030T
(lt)
|
2015-05-18 |
2023-02-27 |
Pieris Pharmaceuticals Gmbh |
Sulietas polipeptidas prieš vėžį
|
|
US10545139B2
(en)
|
2015-06-16 |
2020-01-28 |
Curiox Biosystems Pte Ltd. |
Methods and devices for performing biological assays using magnetic components
|
|
CA2990360C
(en)
|
2015-06-24 |
2024-02-13 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
|
EP3115066A1
(en)
|
2015-07-07 |
2017-01-11 |
Technische Universität München |
Novel psma-specific binding proteins
|
|
CN108348573A
(zh)
*
|
2015-07-15 |
2018-07-31 |
皮里斯制药有限公司 |
Lag-3特异性的新型蛋白
|
|
EA201890456A1
(ru)
|
2015-08-07 |
2018-07-31 |
ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ |
Новый слитый полипептид, специфичный в отношении lag-3 и pd-1
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
JP6622392B2
(ja)
|
2015-10-02 |
2019-12-18 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ１とｔｉｍ３に特異的な二重特異性抗体
|
|
MA43017A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
|
|
CN108271377B
(zh)
|
2015-10-07 |
2021-11-19 |
豪夫迈·罗氏有限公司 |
具有针对共刺激性tnf受体的四价的双特异性抗体
|
|
SG11201803732PA
(en)
|
2015-11-30 |
2018-06-28 |
Pieris Australia Pty Ltd |
Novel anti-angiogenic fusion polypeptides
|
|
TW201725212A
(zh)
|
2015-12-10 |
2017-07-16 |
第一三共股份有限公司 |
特異性於降鈣素基因相關胜肽的新穎蛋白
|
|
WO2017137830A1
(en)
|
2016-02-12 |
2017-08-17 |
Janssen Pharmaceutica Nv |
Anti-vista (b7h5) antibodies
|
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
|
WO2017181139A2
(en)
|
2016-04-15 |
2017-10-19 |
Michael Molloy |
Anti-human vista antibodies and use thereof
|
|
JP7285076B2
(ja)
|
2016-05-11 |
2023-06-01 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｔｎｆファミリーリガンドトリマーとテネイシン結合部分とを含む抗原結合分子
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
EP3512875A2
(en)
|
2016-09-15 |
2019-07-24 |
Quadrucept Bio Limited |
Multimers, tetramers&octamers
|
|
US20190248920A1
(en)
|
2016-09-23 |
2019-08-15 |
Csl Limited |
Coagulation factor binding proteins and uses thereof
|
|
WO2018087108A1
(en)
|
2016-11-09 |
2018-05-17 |
Pieris Pharmaceuticals Gmbh |
Proteins specific for cd137
|
|
WO2018114754A1
(en)
|
2016-12-19 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted 4-1bb (cd137) agonists
|
|
ES2847973T3
(es)
|
2016-12-20 |
2021-08-04 |
Hoffmann La Roche |
Politerapia de anticuerpos biespecíficos anti-CD20/anti-CD3 y agonistas de 4-1BB (CD137)
|
|
MX2019007795A
(es)
|
2017-01-03 |
2019-08-16 |
Hoffmann La Roche |
Moleculas de union a antigeno biespecificas que comprenden el clon 20h4.9 anti-4-1bb.
|
|
WO2018134274A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding affinity for lag-3
|
|
WO2018134279A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptides specific for lag-3 and pd-1
|
|
JP7196094B2
(ja)
|
2017-03-29 |
2022-12-26 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
|
|
CN110382542B
(zh)
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
针对共刺激性tnf受体的双特异性抗原结合分子
|
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
|
RU2766234C2
(ru)
|
2017-04-04 |
2022-02-10 |
Ф. Хоффманн-Ля Рош Аг |
Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap
|
|
CA3052532A1
(en)
|
2017-04-05 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
WO2018185554A1
(en)
|
2017-04-05 |
2018-10-11 |
Curiox Biosystems Pte Ltd. |
Methods, devices, and apparatus for washing samples on array plates
|
|
CN111247165B
(zh)
|
2017-10-18 |
2023-11-10 |
Csl有限公司 |
人血清白蛋白变体及其应用
|
|
JP2021500902A
(ja)
|
2017-11-01 |
2021-01-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
新規ｔｎｆファミリーリガンド三量体含有抗原結合分子
|
|
TW201930353A
(zh)
|
2017-11-01 |
2019-08-01 |
瑞士商赫孚孟拉羅股份公司 |
使用經靶向之ox40促效劑的組合療法
|
|
US20210324108A1
(en)
|
2017-11-01 |
2021-10-21 |
Hoffmann-La Roche Inc. |
Bispecific 2+1 contorsbodies
|
|
CN111417406A
(zh)
|
2017-11-29 |
2020-07-14 |
Csl有限公司 |
治疗或防止缺血-再灌注损伤的方法
|
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
BR112020015568A2
(pt)
|
2018-03-13 |
2020-12-29 |
F. Hoffmann-La Roche Ag |
Agonista de 4-1bb (cd137), produto farmacêutico, composição farmacêutica, uso de uma combinação de um agonista de 4-1bb e método para tratar ou retardar a progressão do câncer
|
|
PE20210652A1
(es)
|
2018-04-13 |
2021-03-26 |
Hoffmann La Roche |
Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl
|
|
EP3810642A1
(en)
|
2018-06-21 |
2021-04-28 |
Technische Universität München |
Hepatitis b and/or hepatitis d-permissive cells and animals
|
|
TW202035447A
(zh)
|
2018-07-04 |
2020-10-01 |
瑞士商赫孚孟拉羅股份公司 |
新穎雙特異性促效性4-1bb抗原結合分子
|
|
FI3830120T3
(fi)
|
2018-07-31 |
2023-06-13 |
Pieris Pharmaceuticals Gmbh |
CD137:lle ja PD-L1:lle spesifinen uusi fuusioproteiini
|
|
JP2022511396A
(ja)
|
2018-10-01 |
2022-01-31 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｃｄ４０への三価結合を伴う二重特異性抗原結合分子
|
|
MA53806A
(fr)
|
2018-10-01 |
2022-01-05 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène comprenant un clone anti-fap 212
|
|
TW202030204A
(zh)
|
2018-12-21 |
2020-08-16 |
瑞士商赫孚孟拉羅股份公司 |
靶向腫瘤之超促效cd28抗原結合分子
|
|
SG11202105093RA
(en)
|
2018-12-21 |
2021-06-29 |
Hoffmann La Roche |
Tumor-targeted agonistic cd28 antigen binding molecules
|
|
AU2020229436A1
(en)
|
2019-02-26 |
2021-07-01 |
Pieris Pharmaceuticals Gmbh |
Novel fusion proteins specific for CD137 and GPC3
|
|
GB201903767D0
(en)
|
2019-03-19 |
2019-05-01 |
Quadrucept Bio Ltd |
Multimers, tetramers & octamers
|
|
KR20210146934A
(ko)
|
2019-03-29 |
2021-12-06 |
아스트라제네카 에이비이 |
천식 치료를 위한 리포칼린 뮤테인
|
|
KR20210146999A
(ko)
|
2019-03-29 |
2021-12-06 |
피어이스 파마슈티컬즈 게엠베하 |
리포칼린 뮤테인의 흡입 투여
|
|
WO2020208049A1
(en)
|
2019-04-12 |
2020-10-15 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising lipocalin muteins
|
|
JP2022538075A
(ja)
|
2019-06-26 |
2022-08-31 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗体結合ｃｅａ及び４－１ｂｂｌの融合
|
|
EP3990492A1
(en)
|
2019-06-27 |
2022-05-04 |
F. Hoffmann-La Roche AG |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
|
EP4054718A1
(en)
|
2019-11-04 |
2022-09-14 |
Pieris Pharmaceuticals GmbH |
Her2/4-1bb bispecific fusion proteins for the treatment of cancer
|
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
|
US20230227568A1
(en)
|
2020-06-05 |
2023-07-20 |
Pieris Pharmaceuticals Gmbh |
Multimeric immunomodulator targeting 4-1bb
|
|
CR20220627A
(es)
|
2020-06-23 |
2023-02-17 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se derigen a her2
|
|
JP2023531067A
(ja)
|
2020-06-25 |
2023-07-20 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｃｄ３／抗ｃｄ２８二重特異性抗原結合分子
|
|
CN117916261A
(zh)
|
2020-11-16 |
2024-04-19 |
豪夫迈·罗氏有限公司 |
与靶向fap的cd40激动剂的组合疗法
|
|
MX2023007174A
(es)
|
2020-12-18 |
2023-09-08 |
Astrazeneca Ab |
Formulacion de polvo seco de muteina de lipocalina para el tratamiento del asma.
|
|
EP4274658A1
(en)
|
2021-01-06 |
2023-11-15 |
F. Hoffmann-La Roche AG |
Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
|
|
MX2023009100A
(es)
|
2021-02-03 |
2023-09-25 |
Mozart Therapeutics Inc |
Agentes aglutinantes y métodos para usar los mismos.
|
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
|
US20240166764A1
(en)
|
2021-03-23 |
2024-05-23 |
Pieris Pharmaceuticals Gmbh |
Her2/4-1bb bispecific fusion proteins for the treatment of cancer
|
|
EP4320141A1
(en)
|
2021-04-08 |
2024-02-14 |
Pieris Pharmaceuticals GmbH |
Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
|
|
WO2022243341A1
(en)
|
2021-05-18 |
2022-11-24 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding affinity for ox40
|
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
|
TW202309078A
(zh)
|
2021-07-02 |
2023-03-01 |
美商建南德克公司 |
治療癌症之方法及組成物
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
WO2023089079A1
(en)
|
2021-11-19 |
2023-05-25 |
Pieris Pharmaceuticals Gmbh |
Novel fusion protein specific for ox40 and pd-l1
|
|
CR20240246A
(es)
|
2021-12-20 |
2024-07-19 |
Hoffmann La Roche |
Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
|
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
|
WO2024056862A1
(en)
|
2022-09-15 |
2024-03-21 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
|
|
TW202428603A
(zh)
|
2022-09-21 |
2024-07-16 |
美商思進公司 |
新穎的cd137及cd228特異性融合蛋白
|
|
GB202216503D0
(en)
|
2022-11-05 |
2022-12-21 |
Quadrucept Bio Ltd |
Non-human vertebrates & cells
|
|
WO2024188965A1
(en)
|
2023-03-13 |
2024-09-19 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
|